» » »

Treatment of Pancreatic Cancer Chico CA

Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say. Pancreatic cancer is resistant to every currently available anti-cancer treatment.

Steven Kent Sterzer, MD
(530) 895-0428
621 Langel Ct
Chico, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ut Sch Of Med, Salt Lake Cty Ut 84132
Graduation Year: 1975
Hospital
Hospital: Enloe Med Ctr -Esplanade, Chico, Ca
Group Practice: Steven K Sterzer Inc

Data Provided by:
Charles H Beach, MD FACS
223 Estates Dr
Chico, CA
Gender
Male
Education
Medical School: Ohio State
Graduation Year: 1948

Data Provided by:
Mark Douglas Fritzler, MD
(530) 898-8405
645 W East Ave Ste 1
Chico, CA
Specialties
Urology
Gender
Male
Education
Medical School: Creighton Univ Sch Of Med, Omaha Ne 68178
Graduation Year: 1981

Data Provided by:
Tadd L Selby
(530) 893-0771
1166 Esplanade
Chico, CA
Specialty
Urology

Data Provided by:
Jack Douglas Hagewood, MD
(530) 891-4259
578 Rio Lindo Ave Ste 3
Chico, CA
Specialties
Urology
Gender
Male
Education
Medical School: Vanderbilt Univ Sch Of Med, Nashville Tn 37232
Graduation Year: 1964

Data Provided by:
Lauren G Smith
(530) 893-1127
572 Rio Lindo Ave
Chico, CA
Specialty
Urology

Data Provided by:
Mark Douglas Fritzler
(530) 898-8405
645 W East Ave
Chico, CA
Specialty
Urology

Data Provided by:
Lauren Glenn Smith, MD
(530) 893-1127
572 Rio Lindo Ave Ste 201
Chico, CA
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ia Coll Of Med, Iowa City Ia 52242
Graduation Year: 1965

Data Provided by:
Tadd L Selby, MD
(530) 893-0771
1166 Esplanade Ste 3
Chico, CA
Specialties
Urology
Gender
Male
Education
Medical School: Loma Linda Univ Sch Of Med, Loma Linda Ca 92350
Graduation Year: 1989

Data Provided by:
Dean Alan Hadley, MD
(530) 872-0220
6283 Clark Rd Ste 3
Paradise, CA
Specialties
Urology
Gender
Male
Education
Medical School: Loma Linda Univ Sch Of Med, Loma Linda Ca 92350
Graduation Year: 1974
Hospital
Hospital: Feather River Hosp, Paradise, Ca

Data Provided by:
Data Provided by:

Treatment of Pancreatic Cancer

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- Inhibiting the action of an enzyme called TAK-1 reverses pancreatic cancer resistance to chemotherapy, a finding that could lead to the development of a new way to treat the disease, researchers say.

Pancreatic cancer is resistant to every currently available anti-cancer treatment.

"During the past few years we have been studying the role played by a cytokine or regulatory protein called transforming growth factor-beta [TGFbeta] in the development of pancreatic cancer. Recently we focused our attention on a unique enzyme activated by TGFbeta, TAK-1, as a mediator for this extreme drug resistance" in pancreatic cancer, study author Dr. Davide Melisi said in a news release from the European Cancer Organization.

He and his colleagues developed a TAK-1 inhibitor and tested it on its own and in combination with the anti-cancer drugs gemcitabine, oxaliplatin and SN-38 (a metabolite of the anti-cancer drug irinotecan) in pancreatic cancer cell lines. They also tested the TAK-1 inhibitor combined with gemcitabine against pancreatic cancer in mice.

"The use of this TAK-1 inhibitor increased the sensitivity of pancreatic cells to all three chemotherapeutic drugs," Melisi said.

"By combining it with classic anti-cancer drugs, we were able to use doses of drugs up to 70 times lower in comparison with the control to kill the same number of cancer cells. In mice, we were able to reduce significantly the tumor volume, to prolong the mice survival, and to reduce the toxicity by combining the TAK-1 inhibitor with very low doses of a classic chemotherapeutic drug, gemcitabine, that would have been ineffective otherwise," Melisi added.

The study was scheduled for presentation Sept. 24 at the joint meeting of the European Cancer Organization and the European Society for Medical Oncology in Berlin.

"This is the first time that TAK-1 has been indicated as a relevant target for the treatment of a solid tumor and that it is a valid approach to reverting the intrinsic drug resistance of pancreatic cancer," Melisi stated. "The TAK-1 inhibitor used in this study is an exciting drug that warrants further development for the treatment of pancreatic cancer."

More information

The American Cancer Society has more about pancreatic cancer.

SOURCE: European Cancer Organization, news release, Sept. 24, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com